387 related articles for article (PubMed ID: 15063962)
1. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
2. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
3. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
4. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
5. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
Belli SH; Graffigna MN; Oneto A; Otero P; Schurman L; Levalle OA
Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
8. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
[TBL] [Abstract][Full Text] [Related]
9. [Use of metformin in the management of adolescents with polycystic ovary syndrome].
Zárate A; Hernández M; Fonseca ME; Ochoa R
Ginecol Obstet Mex; 1997 Dec; 65():504-7. PubMed ID: 9477644
[TBL] [Abstract][Full Text] [Related]
10. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study.
Undén AL; Elofsson S; Brismar K
Clin Endocrinol (Oxf); 2005 Jul; 63(1):94-102. PubMed ID: 15963068
[TBL] [Abstract][Full Text] [Related]
16. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
17. Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome.
Carmina E; Stanczyk FZ; Morris RS; Lee PD; Savjani G; Lobo RA
J Soc Gynecol Investig; 1995; 2(6):743-7. PubMed ID: 9420884
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
[TBL] [Abstract][Full Text] [Related]
19. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
20. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]